Operating Lease, Right-of-Use Asset of Barinthus Biotherapeutics plc. from 31 Dec 2020 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
Barinthus Biotherapeutics plc. quarterly Operating Lease, Right-of-Use Asset in USD history and change rate from 31 Dec 2020 to 30 Sep 2025.
  • Barinthus Biotherapeutics plc. Operating Lease, Right-of-Use Asset for the quarter ending 30 Sep 2025 was $2,063,000, a 72% decline year-over-year.
Source SEC data
View on sec.gov
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Change (%)

Barinthus Biotherapeutics plc. Quarterly Operating Lease, Right-of-Use Asset (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $2,063,000 -$5,381,000 -72% 30 Sep 2025 10-Q 07 Nov 2025 2025 Q3
Q2 2025 $3,323,000 -$3,963,000 -54% 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 $3,855,000 -$3,553,000 -48% 31 Mar 2025 10-Q 07 May 2025 2025 Q1
Q4 2024 $4,384,000 -$3,197,000 -42% 31 Dec 2024 10-Q 07 Nov 2025 2025 Q3
Q3 2024 $7,444,000 -$30,000 -0.4% 30 Sep 2024 10-Q 06 Nov 2024 2024 Q3
Q2 2024 $7,286,000 -$421,000 -5.5% 30 Jun 2024 10-Q 08 Aug 2024 2024 Q2
Q1 2024 $7,408,000 -$315,000 -4.1% 31 Mar 2024 10-Q 13 May 2024 2024 Q1
Q4 2023 $7,581,000 -$172,000 -2.2% 31 Dec 2023 10-K 20 Mar 2025 2024 FY
Q3 2023 $7,474,000 -$84,000 -1.1% 30 Sep 2023 10-Q 09 Nov 2023 2023 Q3
Q2 2023 $7,707,000 -$632,000 -7.6% 30 Jun 2023 10-Q 10 Aug 2023 2023 Q2
Q1 2023 $7,723,000 +$1,024,000 +15% 31 Mar 2023 10-Q 12 May 2023 2023 Q1
Q4 2022 $7,753,000 +$496,000 +6.8% 31 Dec 2022 10-K 20 Mar 2024 2023 FY
Q3 2022 $7,558,000 -$1,222,000 -14% 30 Sep 2022 10-Q 10 Nov 2022 2022 Q3
Q2 2022 $8,339,000 +$6,299,000 +309% 30 Jun 2022 10-Q 09 Aug 2022 2022 Q2
Q1 2022 $6,699,000 +$4,601,000 +219% 31 Mar 2022 10-Q 11 May 2022 2022 Q1
Q4 2021 $7,257,000 +$5,121,000 +240% 31 Dec 2021 10-K 24 Mar 2023 2022 FY
Q3 2021 $8,780,000 30 Sep 2021 10-Q 12 Nov 2021 2021 Q3
Q2 2021 $2,040,000 30 Jun 2021 10-Q 12 Aug 2021 2021 Q2
Q1 2021 $2,098,000 31 Mar 2021 10-Q 14 Jun 2021 2021 Q1
Q4 2020 $2,136,000 31 Dec 2020 10-K 25 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.